Dasatinib Versus Nilotinib as Upfront Therapy for Treatment Naïve Chronic Myeloid Leukemia Chronic Phase
Phase of Trial: Phase III
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Nilotinib (Primary) ; Dasatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms DANIN
- 31 Aug 2018 Biomarkers information updated
- 12 Sep 2017 Planned End Date changed from 1 Jun 2022 to 1 Aug 2022.
- 12 Sep 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Aug 2018.